Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron

NCT02982720 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

4

Enrollment

OTHER

Sponsor class

Stopped Manufacturer discontinued Sylatron

Conditions

Advanced Cholangiocarcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Sylatron

Sponsor

Aiwu Ruth He, MD

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]